FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
Hospital Arnau de Vilanova
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Arnau de Vilanova (97)
2024
-
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
European Journal of Nuclear Medicine and Molecular Imaging
-
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
Breast Cancer Research and Treatment
-
Developmental outcome of electroencephalographic findings in SYNGAP1 encephalopathy
Frontiers in Cell and Developmental Biology, Vol. 12
-
Neurological Disorders in Takotsubo Syndrome: Clinical Phenotypes and Outcomes
Journal of the American Heart Association, Vol. 13, Núm. 4, pp. e032128
2023
-
A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study
Respiratory Research, Vol. 24, Núm. 1
-
Clinical Outcomes of Critical COVID-19 in HIV-Infected Adults: A Propensity Score Matched Analysis
Archivos de Bronconeumologia, Vol. 59, Núm. 11, pp. 772-778
-
Driving pressure and adjunctive therapies in pulmonary sequelae of COVID-19 patients under invasive ventilation
Intensive Care Medicine
-
Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients
Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215
-
Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry
Revista Portuguesa de Cardiologia, Vol. 42, Núm. 3, pp. 237-246
-
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
Blood Cancer Journal, Vol. 13, Núm. 1
-
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 67-80
-
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
The oncologist, Vol. 28, Núm. 1, pp. 23-32
-
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
JAMA Oncology, Vol. 9, Núm. 4, pp. 490-499
-
Relationship between Abdominal Volume Index and Body Adiposity Index and Scales of Insulin Resistance and Metabolic Syndrome
Diagnostics, Vol. 13, Núm. 21
-
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Breast Cancer Research, Vol. 25, Núm. 1
2022
-
ANTES Program: One Year on
Archivos de Bronconeumologia
-
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067
-
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain
Neurologia, Vol. 37, Núm. 8, pp. 615-630
-
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
eBioMedicine, Vol. 75
-
Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries
Frontiers in Cardiovascular Medicine, Vol. 9